SV

Street Verdict

Analyst Scorecard

A record of what JM Financial Analysis said publicly, with the source. Not advice.

“Maintained a 'BUY' rating on Dr Reddy's Laboratories with a target price of ₹1,723, despite tepid US sales in Q3 due to lower generic Revlimid sales and price erosion. Analysts believe the street underappreciates the near-term Semaglutide opportunity in Canada and 18 other markets opening from CY26, with margins expected to be maintained at ~25% post-FY26.”

JM Financial Analysis’s track record (trackable calls only): 213 graded calls · 95% CI 41–54%

Dr Reddy's Laboratories LtdBullishCalled 24 Jan 2025Graded 24 Jan 2026
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹1,723, as stated.

Window: 12 months, the default when no time frame is stated.

Neither the target ₹1,723 was reached on a close by the end of the window. Miss.

The grader’s working: R4 TARGET_CALL: entered ₹1197.65 on 2025-01-27 (next trading session's close); neither target nor stop reached by window end 2026-01-24. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

Tracking Dr Reddy's Laboratories Ltd since this call

1-year tracking window
Read the original articleSee JM Financial Analysis’s full track record